ArticleBlood2009
Genome-wide association study to identify novel loci associated with therapy-related myeloid leukemia susceptibility.
Article in Blood, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 99 citations in OpenAlex.
- Radiation-associated secondary malignancies: a novel opportunity for applying immunotherapies.Cancer immunology, immunotherapy : CII · 2023Review
- Current Landscape of Genome-Wide Association Studies in Acute Myeloid Leukemia: A Review.Cancers · 2023Review
- Article
- Increased Expression of NXPH4 Correlates with Immune Cell Infiltration and Unfavorable Prognosis in Hepatocellular Carcinoma.Journal of oncology · 2022Article
- Genome-Wide Association Analyses Identify Variants inFrontiers in genetics · 2021Article
- Risk of second primary cancers in individuals diagnosed with index smoking- and non-smoking- related cancers.Journal of cancer research and clinical oncology · 2020Article
- Therapy-related acute myeloid leukemia and its prevention.American journal of blood research · 2020Review
- Polymorphisms in IL36G gene are associated with plaque psoriasis.BMC medical genetics · 2019Article
- Risk, Risk Factors, and Surveillance of Subsequent Malignant Neoplasms in Survivors of Childhood Cancer: A Review.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2018Review
- Radiation induced secondary malignancies: a review article.Radiation oncology journal · 2018Article
- Role of Germline Genetics in Identifying Survivors at Risk for Adverse Effects of Cancer Treatment.American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting · 2018Review
- Therapy-related myeloid neoplasms: clinical perspectives.OncoTargets and therapy · 2018Review
- Radiogenomic Predictors of Adverse Effects following Charged Particle Therapy.International journal of particle therapy · 2018Article
- National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Subsequent Neoplasms Working Group Report.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2017Article
- Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study.The Lancet. Oncology · 2017Article
- In silico frameworks for systematic pre-clinical screening of potential anti-leukemia therapeutics.Expert opinion on drug discovery · 2016Review
- Personalized Cancer Risk Assessments for Space Radiation Exposures.Frontiers in oncology · 2016Review
- Autopsy Analysis may Contribute to Establish Actual Incidence of Second Primary Malignancies in Myeloma.Rare tumors · 2015Article
- Myeloid neoplasms after breast cancer: "therapy-related" not an independent poor prognostic factor.Leukemia & lymphoma · 2015Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 2 countries.
Funding
Abstract
Therapy-related acute myeloid leukemia (t-AML) is a rare but fatal complication of cytotoxic therapy. Whereas sporadic cancer results from interactions between complex exposures and low-penetrance alleles, t-AML results from an acute exposure to a limited number of potent genotoxins. Consequently, we hypothesized that the effect sizes of variants associated with t-AML would be greater than in sporadic cancer, and, therefore, that these variants could be detected even in a modest-sized cohort. To test this, we undertook an association study in 80 cases and 150 controls using Affymetrix Mapping 10K arrays. Even at nominal significance thresholds, we found a significant excess of associations over chance; for example, although 6 associations were expected at P less than .001, we found 15 (P(enrich) = .002). To replicate our findings, we genotyped the 10 most significantly associated single nucleotide polymorphisms (SNPs) in an independent t-AML cohort (n = 70) and obtained evidence of association with t-AML for 3 SNPs in the subset of patients with loss of chromosomes 5 or 7 or both, acquired abnormalities associated with prior exposure to alkylator chemotherapy. Thus, we conclude that the effect of genetic factors contributing to cancer risk is potentiated and more readily discernable in t-AML compared with sporadic cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.